Simultaneous targeting of multiple opioid receptors: A strategy to improve side-effect profile

British Journal of Anaesthesia

Volumn 103, Issue 1, 2009, Pages 38-49

  Dietis, N ^a   Guerrini, R ^c   Calo, G ^c   Salvadori, S ^c   Rowbotham, D J ^b   Lambert, D G ^a  

^a Pharmacology and Therapeutics Group   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Analgesics, opioid; Cancer; Pharmacology, opioids; Receptors, opioid; Structure, molecular

Indexed keywords

ANALGESIC AGENT; BINALTORPHIMINE; BIPHALIN; BUTORPHANOL; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE; OXYMORPHONE; LIGAND; NARCOTIC ANALGESIC AGENT;

ADDICTION; ANALGESIA; ANTINOCICEPTION; CHRONIC PAIN; CONSTIPATION; DIMERIZATION; DRUG SYNTHESIS; GENERAL ANESTHESIA; HUMAN; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN TARGETING; RESPIRATION DEPRESSION; REVIEW; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; DRUG TOLERANCE; METHODOLOGY; PAIN; PATHOPHYSIOLOGY;

ANALGESIA; ANALGESICS, OPIOID; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; LIGANDS; PAIN; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 67650726673     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep129     Document Type: Review

References (88)

1. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991; 258: 299-303
2. Addington-Hall J, McCarthy M. Dying from cancer: results of a national population-based investigation. Palliat Med 1995; 9: 295-305
3. Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J 2006; 8: E118-25
4. Ananthan S, Johnson CA, Carter RL, et al. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. J Med Chem 1998; 41: 2872-81
5. Archer S, Glick SD, Bidlack JM. Cyclazocine revisited. Neurochem Res 1996; 21: 1369-73
6. Atcheson R, Lambert DG. Update on opioid receptors. Br J Anaesth 1994; 73: 132-4
7. Balboni G, Fiorini S, Baldisserotto A, et al. Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem 2008; 51: 5109-17
8. Balboni G, Guerrini R, Salvadori S, et al. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem 2002; 45: 713-20
9. Balboni G, Guerrini R, Salvadori S, et al. Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem 2005; 48: 8112-4
10. Balboni G, Onnis V, Congiu C, et al. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem 2006; 49: 5610-7
11. Balboni G, Salvadori S, Guerrini R, et al. Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem 2002; 45: 5556-63
12. Ballet S, Pietsch M, Abell AD. Multiple ligands in opioid research. Protein Pept Lett 2008; 15: 668-82
13. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 2004; 47: 2969-72
14. Black SL, Jales AR, Brandt W, Lewis JW, Husbands SM. The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole. J Med Chem 2003; 46: 314-7
15. Bryant SD, Salvadori S, Cooper PS, Lazarus LH. New delta-opioid antagonists as pharmacological probes. Trends Pharmacol Sci 1998; 19: 42-6
16. Bunzow JR, Saez C, Mortrud M, et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 1994; 347: 284-8
17. Carroll I, Thomas JB, Dykstra LA, et al. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol 2004; 501: 111-9
18. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108
19. Colvin LA, Lambert DG. Pain medicine: advances in basic sciences and clinical practice. Br J Anaesth 2008; 101: 1-4
20. Costa T, Wuster M, Herz A, Shimohigashi Y, Chen HC, Rodbard D. Receptor binding and biological activity of bivalent enkephalins. Biochem Pharmacol 1985; 34: 25-30
21. Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J Med Chem 2005; 48: 1713-6
22. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 2005; 102: 19208-13
23. Fichna J, do-Rego JC, Chung NN, et al. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1), and [Dmt(1), D-2-Nal(4)] endomorphin-2 (Antanal-2). J Med Chem 2007; 50: 512-20
24. Filizola M, Weinstein H. Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. Biopolymers 2002; 66: 317-25
25. Freye E, Latasch L, Portoghese PS. The delta receptor is involved in sufentanil-induced respiratory depression- opioid subreceptors mediate different effects. Eur J Anaesthesiol 1992; 9: 457 - 62
26. Guerrini R, Capasso A, Marastoni M, et al. Rational design of dynor-phin A analogues with delta-receptor selectivity and antagonism for delta- and kappa-receptors. Bioorg Med Chem 1998; 6: 57-62
27. Gupta A, Decaillot FM, Devi LA. Targeting opioid receptor het-erodimers: strategies for screening and drug development. AAPS J 2006; 8: E153-9
28. Harrison C, McNulty S, Smart D, et al. The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells. Br J Pharmacol 1999; 128: 472-8
29. Harrison C, Rowbotham DJ, Grandy DK, Lambert DG. Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor. Br J Pharmacol 2000; 131: 1220-6
30. Hasbi A, Nguyen T, Fan T, et al. Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry 2007; 46: 12997-3009
31. Jiang Q, Mosberg HI, Porreca F. Selective modulation of morphine antinociception, but not development of tolerance, by delta receptor agonists. Eur J Pharmacol 1990; 186: 137-41
32. Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complexes. Neuropsychopharmacology 2000; 23: S5-18
33. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700
34. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 2001; 98: 343-8
35. Kawano S, Ambo A, Sasaki Y. Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide. Bioorg Med Chem Lett 2006; 16: 4839-41
36. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1999; 20: 19-26
37. Koch T, Schulz S, Schroder H, Wolf R, Raulf E, Hollt V. Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated internalization and receptor resensitization. J Biol Chem 1998; 273: 13652-7
38. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 2008; 7: 694-710
39. Lazarus LH, Bryant SD, Cooper PS, Salvadori S. What peptides these deltorphins be. Prog Neurobiol 1999; 57: 377-420
40. Lee SP, O'Dowd BF, George SR. Homo- and heterooligomerization of G protein-coupled receptors. Life Sci 2003; 74: 173-80
41. Lenard NR, Daniels DJ, Portoghese PS, Roerig SC. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 2007; 566: 75-82
42. Levac BA, O'Dowd BF, George SR. Oligomerization of opioid receptors: generation of novel signaling units. Curr Opin Pharmacol 2002; 2: 76-81
43. Li T, Fujita Y, Shiotani K, et al. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem 2005; 48: 8035-44
44. Li T, Fujita Y, Tsuda Y, et al. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J Med Chem 2005; 48: 586-92
45. Li T, Shiotani K, Miyazaki A, et al. Bifunctional [2′ ,6′ -dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/ delta-agonist opioid ligands. J Med Chem 2007; 50: 2753-66
46. Linz K, Kogel B, Schroder W, Cristoph T, Vry J, Friderichs E. Mixed ORL1/mu-agonist for the treatment of pain. Pub. no. US2008/0125475 A1; Pub. date: 29 May 2008. In: Office UP, ed. US Patent Application Publication. US: Grunenthal GMBH Aachen (DE), 2008; 25
47. Lipkowski AW, Konecka AM, Sadowski B. Double enkephalins. Pol J Pharmacol Pharm 1982; 34: 69-71
48. Lipkowski AW, Konecka AM, Sroczynska I, Przewlocki R, Stala L, Tam SW. Bivalent opioid peptide analogues with reduced distances between pharmacophores. Life Sci 1987; 40: 2283-8
49. Lipkowski AW, Misicka A, Davis P, et al. Biological activity of fragments and analogues of the potent dimeric opioid peptide, biphalin. Bioorg Med Chem Lett 1999; 9: 2763-6
50. Liu KS, Hu OY, Ho ST, Tzeng JI, Chen YW, Wang JJ. Antinociceptive effect of a novel long-acting nalbuphine preparation. Br J Anaesth 2004; 92: 712-5
51. Martinka GP, Jhamandas K, Sabourin L, Lapierre C, Lemaire S. Dynorphin A-(1-13)-Tyr14-Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective kappa opioid peptide. Eur J Pharmacol 1991; 196: 161-7
52. Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res 2008; 33: 2142-50
53. Mathews JL, Peng X, Xiong W, et al. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. J Pharmacol Exp Ther 2005; 315: 821-7
54. Metzger TG, Paterlini MG, Portoghese PS, Ferguson DM. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem Res 1996; 21: 1287-94
55. Milligan G. Opioid receptors and their interacting proteins. Neuromol Med 2005; 7: 51-9
56. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341: 33-8
57. Mollica A, Davis P, Ma SW, Lai J, Porreca F, Hruby VJ. Synthesis and biological evaluation of new biphalin analogues with nonhydrazine linkers. Bioorg Med Chem Lett 2005; 15: 2471-5
58. Mollica A, Davis P, Ma SW, Porreca F, Lai J, Hruby VJ. Synthesis and biological activity of the first cyclic biphalin analogues. Bioorg Med Chem Lett 2006; 16: 367-72
59. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005; 48: 6523-43
60. Neumeyer JL, Peng X, Knapp BI, et al. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem 2006; 49: 5640-3
61. Neumeyer JL, Zhang A, Xiong W, et al. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. J Med Chem 2003; 46: 5162-70
62. Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 2002; 22: 10906-13
63. Okada Y, Tsuda Y, Fujita Y, et al. Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia. J Med Chem 2003; 46: 3201-9
64. Ossipov MH, Lai J, King T, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004; 61: 126-48
65. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. J Med Chem 2006; 49: 256-62
66. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem 2007; 50: 2254-8
67. Peng X, Neumeyer JL. Kappa receptor bivalent ligands. Curr Top Med Chem 2007; 7: 363-73
68. Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci 1989; 10: 230-5
69. Portoghese PS. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem 2001; 44: 2259-69
70. Portoghese PS, Garzon-Aburbeh A, Nagase H, Lin CE, Takemori AE. Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine. J Med Chem 1991; 34: 1292-6
71. Portoghese PS, Larson DL, Yim CB, et al. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J Med Chem 1985; 28: 1140-1
72. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 1987; 40: 1287-92
73. Portoghese PS, Lunzer MM. Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord. Eur J Pharmacol 2003; 467: 233-4
74. Portoghese PS, Ronsisvalle G, Larson DL, Yim CB, Sayre LM, Takemori AE. Opioid agonist and antagonist bivalent ligands as receptor probes. Life Sci 1982; 31: 1283-6
75. Salvadori S, Attila M, Balboni G, et al. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med 1995; 1: 678-89
76. Salvadori S, Trapella C, Fiorini S, et al. A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem 2007; 15: 6876-81
77. Sanchez-Blazquez P, Garcia-Espana A, Garzon J. Antisense oligo-deoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Ther 1997; 280: 1423-31
78. Santagada V, Balboni G, Caliendo G, et al. Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorg Med Chem Lett 2000; 10: 2745-8
79. Schiller PW, Fundytus ME, Merovitz L, et al. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 1999; 42: 3520-6
80. Schiller PW, Nguyen TM, Berezowska I, et al. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur J Med Chem 2000; 35: 895-901
81. Shimohigashi Y, Costa T, Chen HC, Rodbard D. Dimeric tetra-peptide enkephalins display extraordinary selectivity for the delta opiate receptor. Nature 1982; 297: 333-5
82. Silbert BS, Lipkowski AW, Cepeda MS, Szyfelbein SK, Osgood PF, Carr DB. Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration. Agents Actions 1991; 33: 382-7
83. Takemori AE, Yim CB, Larson DL, Portoghese PS. Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice. Eur J Pharmacol 1990; 186: 285-8
84. Tancredi T, Salvadori S, Amodeo P, et al. Conversion of enkephalin and dermorphin into delta-selective opioid antagonists by single-residue substitution. Eur J Biochem 1994; 224: 241-7
85. Vergura R, Valenti E, Hebbes CP, et al. Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides 2006; 27: 3322-30
86. Xie Z, Bhushan RG, Daniels DJ, Portoghese PS. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 2005; 68: 1079-86
87. Yeh YC, Lin TF, Lin FS, Wang YP, Lin CJ, Sun WZ. Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. Br J Anaesth 2008; 101: 542-8
88. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-502